Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) EBIT (2022 - 2025)

Historic EBIT for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$11.1 million.

  • Pharmaceuticals' EBIT fell 2657.87% to -$11.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$39.7 million, marking a year-over-year decrease of 4850.36%. This contributed to the annual value of -$39.6 million for FY2024, which is 5797.85% down from last year.
  • Pharmaceuticals' EBIT amounted to -$11.1 million in Q2 2025, which was down 2657.87% from -$10.4 million recorded in Q1 2025.
  • Over the past 5 years, Pharmaceuticals' EBIT peaked at -$3.4 million during Q4 2023, and registered a low of -$15.0 million during Q4 2022.
  • Its 4-year average for EBIT is -$8.2 million, with a median of -$8.0 million in 2023.
  • Over the last 5 years, Pharmaceuticals' EBIT had its largest YoY gain of 7710.3% in 2023, and its largest YoY loss of 4622.12% in 2023.
  • Over the past 4 years, Pharmaceuticals' EBIT (Quarter) stood at -$15.0 million in 2022, then soared by 77.1% to -$3.4 million in 2023, then tumbled by 156.46% to -$8.8 million in 2024, then dropped by 26.58% to -$11.1 million in 2025.
  • Its EBIT stands at -$11.1 million for Q2 2025, versus -$10.4 million for Q1 2025 and -$8.8 million for Q2 2024.